AXIOS October 31, 2023
The push to use psychedelics as treatment for veterans with PTSD is gaining momentum across the country — and the Bay Area is taking the lead.
Why it matters: Studies show that MDMAs reduce PTSD symptoms and functional impairment. Advocates are working to secure FDA approval of its use in a bid to more effectively tackle the suicide epidemic among veterans.
State of play: Veterans Affairs Palo Alto is gearing up to recruit and screen participants for its own clinical trials with MDMA-assisted therapy, according to Stanford psychiatry professor Trisha Suppes, who is overseeing the research.
- Under current protocol, patients are administered the compound three times over a 12- to 14-week period in a controlled, supervised setting with therapists. ...